Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study population

From: Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

  Control group (n = 15) Prehabilitation group (n =14) p-value
Age (years), mean ± SD 63.8 ± 7.6 65.1 ± 10.2 0.689
BMI (kg/m2), mean ± SD 27.2 ± 5.7 29.3 ± 6.1 0.360
Disease stage, n (%)
 III 8 (53.3) 7 (50.0) 0.858
 IV 7 (46.7) 7 (50.0)
Medical history, n (%)
 Heart disease 2 (13.3) 1 (7.1) 0.584
 Diabetes 2 (13.3) 3 (21.4) 0.564
 Anticoagulation 2 (13.3) 0 (0) 0.157
Smoking 6 (40.0) 3 (21.4) 0.270
Alcohol 2 (13.3) 0 (0) 0.157
ASA class, n (%)
 II 6 (40.0) 9 (64.3) 0.323
 III 8 (53.3) 5 (35.7)
 IV 1 (6.7) 0 (0)
Time between diagnosis and interval surgery (weeks), mean ± SD [range] 15.3 ± 3.2 [11.3–24.3] 13.5 ± 2.0 [11.4–18.0] 0.097
  1. ASA American Society of Anesthesiologists, BMI body mass index, COPD chronic obstructive pulmonary disease, SD standard deviation